Pre-treatment plasma levels of cachexia related immune mediators (such as osteopontin and pentraxin‐3) are found to associate with outcome of advanced or recurrent NSCLC patients receiving PD‐1/PD‐L1 inhibitor monotherapy (31). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.